X

Trial Profile

Sevuparin as a potential adjunctive therapy in children with severe malaria: Phase I safety and dose-finding trial

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sevuparin (Primary) ; Antimalarials
Indications Falciparum malaria
Focus Adverse reactions
Acronyms SEVUSMART

Most Recent Events

18 Aug 2023 Planned End Date changed from 15 Jul 2023 to 15 Jul 2024.
18 Aug 2023 Status changed from recruiting to active, no longer recruiting.
01 Sep 2022 According to a Modus Therapeutics media release, this trial is the result of a collaboration between Modus and a team led by Professor Kathryn Maitland from Imperial College London, UK.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com